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Discussion 
Chemotherapy for malignancy is fraught with 
potential side effects and complications.  In 
choosing a chemotherapy regimen, the physician 
and patient must consider the risks, benefits, and 
individual patient goals. Some patients seek the 
services of integrative medicine which offers 
alternative therapies, such as high dose Vitamin C 
for malignant mesothelioma, but these too are not 
without risk. 
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Conclusion 
A 77 year-old male with a history of asbestos 
exposure and malignant mesothelioma  was 
transferred from an outside hospital after presenting 
with pleuritic pain and acute on chronic renal failure 
with a creatinine of 10.01. 
•  Mesothelioma was diagnosed one year prior.  At 
diagnosis, he declined aggressive chemotherapy due 
to risk of toxicity and opted for high dose Vitamin C 
infusion with nutritional therapy.  
•  The patient was critically ill on presentation with a 
severe anion gap metabolic acidosis with underlying 
metabolic alkalosis. His creatinine was 10.01 
(baseline one month prior 1.97) and BUN was 104.  
•  The etiology of the patient’s acute onset of renal 
failure was initially unclear, and a diagnostic workup 
ensued. 
•Urine electrolyte analysis was consistent with an 
intrinsic pathology. 
•Microscopic evaluation revealed oxalate crystals 
(example shown on Figure 1).  
•Ultrasound with bilateral calculi and increased 
echogenicity was consistent with oxalate deposition. 
(Figure 2) 
• These findings were consistent with high dose 
Vitamin C toxicity as no alternative ingestion causing 
oxalate crystals was identified.   
• Unfortunately, his clinical situation deteriorated over 
the hospital course.  A CT of the chest revealed 
progressive mesothelioma, and his renal failure  was 
irreversible. Hypoxic respiratory failure secondary to 
hypervolemia resulted.  The patient declined dialysis 
and switched his goals to pure palliation.  
 
Figure 2: Right  renal US with calculi (marked by circle) and increased renal  
cortical echogenicity.  
Figure 1: Example of  rhomboid-shaped oxalate crystals as found in this patient.   
Although this therapy is generally well 
tolerated, caution should be taken when using 
high dose Vitamin C in patients with renal 
failure as toxicity from oxalate deposition is 
more likely to occur.  In combination with the 
findings of the previous case report, this case 
produces further evidence that oxalate 
deposition is a potential adverse effect that can 
have detrimental outcomes.  
•High dose Vitamin C therapy has been studied 
in the treatment of multiple disease processes, 
including advanced malignancies.   
•Vitamin C has been shown to increase host 
resistance through boosted immunity.  
•The clinical benefit of high dose Vitamin C 
in malignancy is mixed. 
•Active clinical trials are ongoing including a 
weekly 50 gram Vitamin C infusion study in 
which our patient was enrolled. 
•Although nutritional therapies are seemingly 
less toxic than traditional chemotherapy options, 
they are not without risks.  
•High dose Vitamin C has been shown to 
induce calcium oxalate stone formation 
resulting in hyperoxaluria. 
•The mechanism of action is a conversion of 
ascorbate to oxalate leading to hyperoxaluria.  
•The use of Vitamin C in dialysis patients is 
controversial. 
•Hyperoxaluria has been demonstrated at 
doses of 1-2 grams of Vitamin C daily. 
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